Dr. Long-Cheng Li Receives Prestigious Award for ALS Research
Ractigen Therapeutics is excited to share the news that its Founder and CEO, Dr. Long-Cheng Li, has been awarded the 2024 Life Science Ice Breaking Award. This prestigious accolade, created by notable ALS advocate Cai Lei and his wife Duan Rui, celebrates remarkable advancements in ALS research and treatment that make a real difference for patients.
Understanding ALS and Ractigen's Commitment
Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative condition affecting motor neurons, leading to severe muscle weakness and, ultimately, respiratory failure. Despite extensive research over many years, effective treatments for ALS have been elusive. Ractigen Therapeutics has dedicated itself to overcoming these challenges using cutting-edge RNA technology to craft innovative therapies that address ALS at its genetic roots.
The Role of RAG-17 in ALS Treatment
One of the focal points of Ractigen's research is RAG-17, a small interfering RNA (siRNA) therapy specifically engineered to target the SOD1 gene, crucial for certain ALS forms. Utilizing Ractigen's unique SCAD™ delivery system, RAG-17 ensures efficient and sustained delivery to the central nervous system. This approach not only reduces toxic levels of the SOD1 protein but also aims to slow disease progression while preserving the functionality of motor neurons. Preliminary studies have shown promising results, including enhanced survival rates and improved motor functions in animal models. RAG-17 is currently moving forward into Phase I clinical trials, signaling a hopeful development in ALS treatment.
Advancing with RAG-21
In addition, Ractigen is advancing RAG-21, a groundbreaking therapy that focuses on FUS gene mutations associated with more aggressive ALS types. Receiving Orphan Drug Designation from the U.S. FDA underlines RAG-21's potential to meet the critical needs of patients by targeting the core genetic issues underlying their condition.
Dr. Li's Broader Contributions to RNA Therapeutics
Dr. Long-Cheng Li's influence on the field of RNA therapeutics extends well beyond his work with ALS. He is the visionary behind RNA Activation (RNAa), a transformative method in gene expression regulation, garnering him profound recognition globally. His leadership has reinforced Ractigen's position as a pioneer in the development of various RNA-based drugs, focusing on unmet medical needs across several disease categories, including neurodegenerative disorders, cancers, metabolic diseases, and others.
The Significance of the Life Science Ice Breaking Award
The Life Science Ice Breaking Award acknowledges Dr. Li's exceptional contributions, backed by a rewarding prize of RMB 5 million. This acknowledgment reflects the hopes and dedication of patient communities striving for progress in ALS research. The award emphasizes the essential nature of actual patient impact, driving the transformation of scientific advancements into impactful therapies.
In Dr. Li's words, "This award reinforces our dedication to Ractigen's mission to create life-changing therapies addressing critical health challenges like ALS. We are committed to scientific progress and to delivering significant solutions for patients globally."
Ractigen's Future Aspirations
Ractigen Therapeutics remains focused on its commitment to advancing therapeutic options like RAG-17 and RAG-21. The company's drive towards innovation seeks to continue unlocking solutions for rare diseases through state-of-the-art RNA-based drug development. With a vision of providing hope and healing, Ractigen endeavours to assist patients confronting significant medical challenges that have long been unanswered.
About Ractigen Therapeutics
Ractigen Therapeutics stands out as a leader in small activating RNA (saRNA) research, working tirelessly to develop saRNA medications that utilize the RNA activation (RNAa) mechanism, promoting healthy gene expression. This inventive approach allows for the targeting of specific genes to restore normal protein function. Ractigen is the sole entity globally advancing both saRNA and siRNA therapies into clinical trials. Additionally, the company boasts expertise in both liver-targeted and extra-hepatic oligonucleotide delivery systems, positioning itself at the forefront of treating diseases that present challenges to traditional treatment pathways.
Frequently Asked Questions
What is the Life Science Ice Breaking Award?
This award recognizes significant contributions to ALS research and patient care, focusing on tangible impacts for individuals affected by ALS.
Who is Dr. Long-Cheng Li?
Dr. Long-Cheng Li is the Founder and CEO of Ractigen Therapeutics, recognized for his pioneering work in RNA therapeutics and ALS research.
What does RAG-17 target?
RAG-17 specifically targets the SOD1 gene, which plays a critical role in certain forms of ALS.
Why is RAG-21 important?
RAG-21 addresses FUS gene mutations, a factor in aggressive ALS types, and has received Orphan Drug Designation from the FDA.
What is Ractigen's mission?
Ractigen is dedicated to advancing RNA-based therapies to meet unaddressed medical needs and improve patient outcomes worldwide.
